For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>CP21R7 is a potent and selective GSK-3β inhibitor.<br>CP21R7 can inhibitor enhances the induction of KDR+precursors prior to vascular commitment.Cp21R7 compound induced the highest luciferase activity at a concentration of 3 μ M.[2] Immunofluorescence staining revealed that CP21 significantly increased total levels of intracellular -catenin. Activation of WNT signaling via GSK3 inhibition with CP21 induced commitment of hPSCs towards mesoderm. [3]</p>
Catalog Number | I001003 |
CAS Number | 125314-13-8 |
Synonyms | 3-(3-aminophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione |
Molecular Formula | C₁₉H₁₅N₃O₂ |
Purity | ≥95% |
Target | Stem Cell/Wnt |
Solubility | DMSO: ≥ 34 mg/mL |
Storage | Store at -20°C |
InChI | InChI=1S/C19H15N3O2/c1-22-10-14(13-7-2-3-8-15(13)22)17-16(18(23)21-19(17)24)11-5-4-6-12(20)9-11/h2-10H,20H2,1H3,(H,21,23,24) |
InChIKey | RGTAEYDIDMGJLX-UHFFFAOYSA-N |
SMILES | CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CC(=CC=C4)N |
Reference | <p style=/line-height:25px/> <br>[2]. K. christensen et al. Method for differentiation of pluripotent stem cells into vascular bed cells. Application number, CN 201280028159, Mar 5, 2014. <br>[3]. Christoph Patsch et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol, 2015 Aug, 17(8): 994-1003. </p> |